Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 834 - Thirty-third Report
(1993; 36 pages) View the PDF document
Table of Contents
View the documentWHO Expert Committee on Specifications for Pharmaceutical Preparations
View the document1. Introduction
Open this folder and view contents2. The international pharmacopoeia and related activities
Open this folder and view contents3. International Chemical Reference Substances and International Infrared Reference Spectra
View the document4. Quality control methods for medicinal plant materials
View the document5. The WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce
Open this folder and view contents6. Good manufacturing practices for pharmaceutical products
View the document7. Development of globally acceptable standards for excipients
Open this folder and view contents8. Stability of dosage forms
View the document9. Simple test methodology
View the document10. Quality assurance in pharmaceutical supply systems
Open this folder and view contents11. Pharmaceutical production in developing countries
View the document12. Training
View the documentAcknowledgements
View the documentReferences
View the documentAnnex 1 - List of available International Chemical Reference Substances1
View the documentAnnex 2 - List of available International Infrared Reference Spectra
Open this folder and view contentsAnnex 3 - Good manufacturing practices for biological products1
View the documentBack Cover
 

Acknowledgements

Special acknowledgement was made by the Committee to Dr S. Kopp-Kubel, Regulatory Support, and Miss M. Schmid, Quality Assurance, Division of Drug Management and Policies, WHO, Geneva, Switzerland, who were both instrumental in the preparation and proceedings of the meeting.

The Committee also acknowledged with thanks the valuable contributions made to its work by the following institutions and persons:

WHO Collaborating Centre for Drug Quality Control, Therapeutic Goods Administration Laboratories, Department of Community Services and Health, Woden, Australian Capital Territory, Australia; WHO Collaborative Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Temple of Heaven, Beijing, China; WHO Collaborating Centre for Biopharmaceutical Aspects of Drug Quality Control, Biopharmacy Laboratory, Faculty of Pharmacy, University of Clermont-Ferrand, Clermont-Ferrand, France; WHO Collaborating Centre for Stability Studies of Drugs, Regional and University Hospital Centre, Nantes, France; WHO Collaborating Centre for Drug Information and Quality Assurance, National Institute of Pharmacy, Budapest, Hungary; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Central Drugs Laboratory, Government of India, Calcutta, India; WHO Collaborating Centre for Quality Assurance of Essential Drugs, The National Quality Control Laboratory of Drug and Food, Directorate General of Drug and Food Control, Ministry of Health, Jakarta, Indonesia; WHO Collaborating Centre for Chemical Reference Substances, The National Corporation of Swedish Pharmacies, Central Laboratory, Stockholm, Sweden; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Department of Medical Sciences, Ministry of Public Health, Bangkok, Thailand; WHO Collaborating Centre for Drug Quality Control, State Research Institute for the Standardization and Control of Drugs, Ministry of Health, Moscow, Russian Federation.

Professor J.-M. Aiache, Biopharmacy Laboratory, Faculty of Pharmacy, University of Clermont-Ferrand, France; Dr S. L. Ali, Association of German Pharmacists’ Central Laboratory, Eschborn, Germany; Dr H. Altdorfer, Pharmaceutical Institute, Swiss Federal Institute of Technology, Zurich, Switzerland; Professor E. Doelker, University of Geneva, Switzerland; Dr M.A. Kaukinen, Pharmaceutical Chemical Division, National Medicines Control Laboratory, Helsinki, Finland; Dr E. Keller, Ciba-Geigy, Basel, Switzerland; Dr S. Kliouev, Certification Department, Institute of Technology and Safety of Drugs, Moscow, Russian Federation; Dr T Layloff, Division of Drug Analysis, Food and Drug Administration, St Louis, MO, USA; Dr J. D. Nicholson, PSGB Medicines Testing Laboratory Edinburgh, Scotland; Professor L Ogunlana, Lanpharm Laboratory, Lagos, Nigeria; Dr S. Okada, Division of Drugs, National Institute of Hygienic Sciences, Osaka, Japan; Professor J. Richter, Berlin, Germany; Mr J. L. Turner, Medicines Control Agency, Department of Health, London, England; Dr W. Wieniawski, Polish Pharmacopoeia Commission, Warsaw, Poland.

Unfortunately the Committee was not in a position to name all those who contributed to the development of its report but wished to extend its thanks to them for their support.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014